Mass cytometric single cell immune profiles of peripheral blood from acute myeloid leukemia patients in complete remission with measurable residual disease.

Autor: Sefland Ø; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway.; Department of Medicine, Section of Hematology, Haukeland University Hospital, Bergen, Norway.; K.G. Jebsen Centre for Myeloid Blood Cancer, Department of Clinical Science, University of Bergen, Bergen, Norway., Gullaksen SE; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway.; Department of Medicine, Section of Hematology, Haukeland University Hospital, Bergen, Norway.; K.G. Jebsen Centre for Myeloid Blood Cancer, Department of Clinical Science, University of Bergen, Bergen, Norway., Omsland M; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway.; K.G. Jebsen Centre for Myeloid Blood Cancer, Department of Clinical Science, University of Bergen, Bergen, Norway.; Department of Safety, Chemistry, and Biomedical Laboratory Sciences, Western Norway University of Applied Sciences, Bergen, Norway., Reikvam H; Department of Medicine, Section of Hematology, Haukeland University Hospital, Bergen, Norway.; K.G. Jebsen Centre for Myeloid Blood Cancer, Department of Clinical Science, University of Bergen, Bergen, Norway.; Department of Clinical Science, University of Bergen, Bergen, Norway., Galteland E; Department of Haematology, Oslo University Hospital, Oslo, Norway., Tran HTT; Department of Haematology, Akershus University Hospital, Lørenskog, Norway., Spetalen S; Department of Pathology, Oslo University Hospital, Oslo, Norway., Singh SK; Mendus A.B., Stockholm, Sweden., Van Zeeburg HJT; Mendus A.B., Stockholm, Sweden., Van De Loosdrecht AA; Department of Hematology, Amsterdam University Medical Center, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, Netherlands., Gjertsen BT; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway.; Department of Medicine, Section of Hematology, Haukeland University Hospital, Bergen, Norway.; K.G. Jebsen Centre for Myeloid Blood Cancer, Department of Clinical Science, University of Bergen, Bergen, Norway.
Jazyk: angličtina
Zdroj: Cytometry. Part B, Clinical cytometry [Cytometry B Clin Cytom] 2024 Nov; Vol. 106 (6), pp. 485-496. Date of Electronic Publication: 2024 Jul 30.
DOI: 10.1002/cyto.b.22197
Abstrakt: Measurable residual disease (MRD) is detected in approximately a quarter of AML chemotherapy responders, serving as a predictor for relapse and shorter survival. Immunological control of residual disease is suggested to prevent relapse, but the mechanisms involved are not fully understood. We present a peripheral blood single cell immune profiling by mass cytometry using a 42-antibody panel with particular emphasis on markers of cellular immune response. Six healthy donors were compared with four AML patients with MRD (MRD + ) in first complete remission (CR1 MRD+ ). Three of four patients demonstrated a favorable genetic risk profile, while the fourth patient had an unfavorable risk profile (complex karyotype, TP53-mutation) and a high level of MRD. Unsupervised clustering using self-organizing maps and dimensional reduction analysis was performed for visualization and analysis of immune cell subsets. CD57 + natural killer (NK)-cell subsets were found to be less abundant in patients than in healthy donors. Both T and NK cells demonstrated elevated expression of activity and maturation markers (CD44, granzyme B, and phosho-STAT5 Y694) in patients. Although mass cytometry remains an expensive method with limited scalability, our data suggest the utility for employing a 42-plex profiling for cellular immune surveillance in whole blood, and possibly as a biomarker platform in future clinical trials. The findings encourage further investigations of single cell immune profiling in CR1 MRD+ AML-patients.
(© 2024 The Author(s). Cytometry Part B: Clinical Cytometry published by Wiley Periodicals LLC on behalf of International Clinical Cytometry Society.)
Databáze: MEDLINE
Externí odkaz: